3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colorectal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
4
Magnetic Resonance Spectroscopy
4
trametinib
3
selpercatinib
3
Trastuzumab
3
ulixertinib
2
larotrectinib
2
binimetinib
2
belinostat
2
alectinib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy
2
Paclitaxel
2
Nivolumab
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Biopsy
2
130-nm albumin-bound paclitaxel
2
vandetanib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
tipifarnib
1
spartalizumab
1
sargramostim
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
naporafenib
×
Thoracic
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled